간행물 검색
- 현재 페이지 경로
-
- HOME
- 간행물
- 간행물 검색
| 논문분류 | 춘계학술대회 초록집 |
|---|---|
| 제목 | A Novel Therapeutic Strategy of ADPKD |
| 저자 | YOSHITAKA ISAKA |
| 출판정보 | 2019; 2019(1): |
| 키워드 | ADPKD | tolvaptan | TEMPO3:4 |
| 초록 | Autosomal dominant polycystic kidney disease (ADPKD) is a widespread genetic disease that leads to renal failure in the majority of patients. Tolvaptan is a highly selective vasopressin V2 receptor antagonist indicated for use in patients with ADPKD. In the large phase III TEMPO 3:4 trial in adults with ADPKD, 3 years` treatment with oral tolvaptan significantly reduced growth in total kidney volume and slowed renal function decline relative to placebo. Subsequent clinical studies also showed the effectiveness of tolvaptan in patients with ADPKD. Here, I would like to discuss the therapeutic strategies for ADPKD patients. |
| 원문(PDF) | PDF 원문보기 |
(06022) 서울시 강남구 압구정로 30길 23 미승빌딩 301호
- Tel: 02)3486-8736
- Fax: 02)3486-8737
- E-mail: ksn@ksn.or.kr
- 사업자 등록번호: 208-82-60817
- 대표자: 박형천
Copyright© 대한신장학회. All right reserved.
